PE20040067A1 - NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE - Google Patents

NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE

Info

Publication number
PE20040067A1
PE20040067A1 PE2003000512A PE2003000512A PE20040067A1 PE 20040067 A1 PE20040067 A1 PE 20040067A1 PE 2003000512 A PE2003000512 A PE 2003000512A PE 2003000512 A PE2003000512 A PE 2003000512A PE 20040067 A1 PE20040067 A1 PE 20040067A1
Authority
PE
Peru
Prior art keywords
crobenetine
parenteral administration
new formulation
biii
concentration
Prior art date
Application number
PE2003000512A
Other languages
Spanish (es)
Inventor
Bernd Kruss
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040067A1 publication Critical patent/PE20040067A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

QUE COMPRENDE: i)MANITOL; Y, ii)BIII 890 O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; Y, iii)UN TAMPON DE ACIDO ACETICO/ACETATO, QUE TIENE QUE TIENE UNA CONCENTRACION MOLAR ENTRE 0,05 Y 0,5 Y UN VALOR DE pH DE 3,8 A 5. DONDE, SE UTILIZA COMO SUSTANCIA ACTIVA EL HIDROCLORURO DE BIII 890 EN UNA CONCENTRACION DE 0,1 mg/ml A 3 mg/ml. LA COMPOSICION DESCRITA SE APLICA POR VIA PARENTERAL O INTRAVENOSA PARA EL TRATAMIENTO DE ACCIDENTE CEREBROVASCULARWHICH INCLUDES: i) MANNITOL; AND, ii) BIII 890 OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS; AND, iii) AN ACETIC ACID / ACETATE BUFFER, WHICH HAS A MOLAR CONCENTRATION BETWEEN 0.05 AND 0.5 AND A pH VALUE OF 3.8 TO 5. WHERE, BIII HYDROCHLORIDE IS USED AS THE ACTIVE SUBSTANCE 890 AT A CONCENTRATION OF 0.1 mg / ml TO 3 mg / ml. THE DESCRIBED COMPOSITION IS APPLIED BY THE PARENTERAL OR INTRAVENOUS ROUTE FOR THE TREATMENT OF CEREBROVASCULAR ACCIDENT

PE2003000512A 2002-05-29 2003-05-27 NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE PE20040067A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223784A DE10223784A1 (en) 2002-05-29 2002-05-29 New formulation for parenteral administration of crobenetine

Publications (1)

Publication Number Publication Date
PE20040067A1 true PE20040067A1 (en) 2004-03-30

Family

ID=29432394

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000512A PE20040067A1 (en) 2002-05-29 2003-05-27 NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE

Country Status (10)

Country Link
EP (1) EP1511487A1 (en)
JP (1) JP2005531573A (en)
AR (1) AR040135A1 (en)
AU (1) AU2003240699A1 (en)
CA (1) CA2487153A1 (en)
DE (1) DE10223784A1 (en)
PE (1) PE20040067A1 (en)
TW (1) TW200406205A (en)
UY (1) UY27824A1 (en)
WO (1) WO2003099280A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10223783A1 (en) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma New formulation for parenteral administration of a Na-channel blocker

Also Published As

Publication number Publication date
AR040135A1 (en) 2005-03-16
DE10223784A1 (en) 2003-12-11
JP2005531573A (en) 2005-10-20
AU2003240699A1 (en) 2003-12-12
TW200406205A (en) 2004-05-01
UY27824A1 (en) 2003-12-31
WO2003099280A1 (en) 2003-12-04
CA2487153A1 (en) 2003-12-04
EP1511487A1 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
PE20030399A1 (en) FORMS OF ADMINISTRATION OF PROPIVERINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS WITH PROLONGED RELEASE OF THE ACTIVE SUBSTANCE
CY1114000T1 (en) STABILIZED TERIPARATIDE SOLUTIONS
PE20030575A1 (en) STABLE AND HIGHLY CONCENTRATED MELOXICAM SOLUTIONS FOR NEEDLELESS INJECTION
BR9912694A (en) Compound to prepare pulmonary administration medication
PT1299107E (en) VERY CONCENTRATED SOLUTIONS OF MELOXICAM
BRPI0409185A (en) topical anthelmintic veterinary formulations
NO20062713L (en) 2.6 bis-heteroaryl-4-aminopyrimidines as adenosine receptor antagonists
PE20061437A1 (en) COMPOSITION IN EMULSION INCLUDING DERIVATIVES OF CYCLOALKENE, STABLE IN ACID RANGE
PE20050822A1 (en) FLORPHENICOL DERIVATIVES WITH BETTER SOLUBILITY IN WATER
CL2009001899A1 (en) Pharmaceutical composition comprising: i) an at1 receptor antagonist or a salt, ii) an insulin sensitizer or a salt and iii) a pharmaceutically acceptable carrier; use for the prevention, delay of progress or treatment of hypertension, diabetes, among others (div. sol. 2034-01).
PE20010053A1 (en) AMOXICILLIN AND POTASSIUM CLAVULANATE FORMULATION
AR082049A1 (en) LIQUID FORMULATIONS OF RUPATADINA FUMARATO
AR029373A1 (en) METHOD FOR THE TREATMENT OF MIGRANES, USING SELECTIVE ANTAGONIST COMPOUNDS OF THE IGLUR5 RECEPTORS, USE OF SUCH SELECTIVE ANTAGONIST COMPOUNDS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF MIGRANES AND SAVINGS COMPOSED
CO5251448A1 (en) SOLUTIONS CONTAINING EPINASTINE
ES2224917T1 (en) PHARMACEUTICAL COMPOSITIONS OF FIBRINOLITIC AGENT.
WO2001047913A3 (en) Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect
ATE367165T1 (en) REEPITHELIALIZING PHARMACEUTICAL PREPARATIONS CONTAINING XANTHANG GUM
DK1401405T3 (en) Oral, pharmaceutical compositions with improved bioavailability
AR031649A1 (en) DRONEDARONA PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION
WO2006095363A3 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts
PE20060484A1 (en) LIQUID PHARMACEUTICAL PREPARATIONS CONTAINING A BENZHYDRIL PIPERIZINE COMPOUND
AR016382A1 (en) USE OF A BENCIL-INDAZOL METOXIALCANOIC ACID DERIVATIVE.
PE20040067A1 (en) NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE
BR0013283A (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
PE20030092A1 (en) FORMULATION OF AN INHALATION SOLUTION WITH A TIOTROPE SALT

Legal Events

Date Code Title Description
FA Abandonment or withdrawal